Technology area: Medical Devices & Mechanical Engineering
8 pending office actions • 2 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Setpoint Medical Corporation has 8 pending office actions in Medical Devices & Mechanical Engineering. The docket involves 7 examiners but only 2 art units, indicating that several examiner relationships are concentrated within a small technical-group structure. Art-unit coordination may therefore provide a useful foundation for portfolio management.
JIAN, SHIRLEY XUEYING is the busiest examiner, with 2 pending matters. Counsel should compare those matters for recurring issues while recognizing that the other examiner assignments may present different approaches. Consistent device terminology and disclosure positions can be paired with examiner-specific amendments and arguments.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JIAN, SHIRLEY XUEYING | 2 | 63.3% | +22.8% |
| MARLEN, TAMMIE K | 1 | 75.3% | +20.8% |
| ROBLES, EILEEN | 1 | 100.0% | +0.0% |
| GRAY, PHILLIP A | 1 | 74.1% | +10.8% |
| STEINBERG, AMANDA L | 1 | 51.7% | +26.1% |
| SISON, CHRISTINE ANDREA PAN | 1 | 32.7% | +40.7% |
| LEE, ERICA SHENGKAI | 1 | 65.4% | +29.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18893907 | CONTROL OF VAGAL STIMULATION | ROBLES, EILEEN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18664817 | REVERSING DEMYELINATION | JIAN, SHIRLEY XUEYING | 8d overdue |
| 17700415 | SYSTEMS AND METHODS FOR ESTABLISHING A NERVE BLOCK | LEE, ERICA SHENGKAI | 4d overdue |
| 18730753 | TREATMENT OF INFLAMMATORY DISORDERS | GRAY, PHILLIP A | — |
| 18605809 | BIMODAL VAGUS NERVE STIMULATION TO TREAT NEURODEGENERATIVE DISORDERS | STEINBERG, AMANDA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18295251 | VAGUS NERVE STIMULATION TO TREAT NEURODEGENERATIVE DISORDERS | SISON, CHRISTINE ANDREA PAN | 53d overdue |
| 18664817 | REVERSING DEMYELINATION | JIAN, SHIRLEY XUEYING | 8d overdue |
| 17700415 | SYSTEMS AND METHODS FOR ESTABLISHING A NERVE BLOCK | LEE, ERICA SHENGKAI | 4d overdue |
| 19235529 | EXTREMELY LOW DUTY-CYCLE ACTIVATION OF THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY TO TREAT CHRONIC INFLAMMATION | MARLEN, TAMMIE K | — |
| 19224699 | TREATMENT OF MULTIPLE SCLEROSIS | JIAN, SHIRLEY XUEYING | — |
| 18730753 | TREATMENT OF INFLAMMATORY DISORDERS | GRAY, PHILLIP A | — |
| 18605809 | BIMODAL VAGUS NERVE STIMULATION TO TREAT NEURODEGENERATIVE DISORDERS | STEINBERG, AMANDA L | — |
| Art Unit | Apps |
|---|---|
| 3792 | 4 |
| 3796 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19235529 | EXTREMELY LOW DUTY-CYCLE ACTIVATION OF THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY TO TREAT CHRONIC INFLAMMATION | MARLEN, TAMMIE K | 3796 | §102§103DP | Non-Final OA | — | Pending | Jun 11, 2025 |
| 19224699 | TREATMENT OF MULTIPLE SCLEROSIS | JIAN, SHIRLEY XUEYING | 3792 | §103Other | Non-Final OA | — | Pending | May 30, 2025 |
| 18893907 | CONTROL OF VAGAL STIMULATION | ROBLES, EILEEN | 3792 | §103Other | Final Rejection | — | Pending | Sep 23, 2024 |
| 18730753 | TREATMENT OF INFLAMMATORY DISORDERS | GRAY, PHILLIP A | — | §103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18664817 | REVERSING DEMYELINATION | JIAN, SHIRLEY XUEYING | 3792 | §103§112Other | Final Rejection | 8d overdue | Pending | May 15, 2024 |
| 18605809 | BIMODAL VAGUS NERVE STIMULATION TO TREAT NEURODEGENERATIVE DISORDERS | STEINBERG, AMANDA L | 3792 | §102§103 | Final Rejection | — | Pending | Mar 14, 2024 |
| 18295251 | VAGUS NERVE STIMULATION TO TREAT NEURODEGENERATIVE DISORDERS | SISON, CHRISTINE ANDREA PAN | 3796 | §112 | Final Rejection | 53d overdue | Pending | Apr 03, 2023 |
| 17700415 | SYSTEMS AND METHODS FOR ESTABLISHING A NERVE BLOCK | LEE, ERICA SHENGKAI | 3796 | §103§112 | Non-Final OA | 4d overdue | Pending | Mar 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSetpoint Medical Corporation has 8 pending office actions as of October 2026, spread across 2 art units and 7 examiners.
Shirley Xueying Jian has the most, with 2 of Setpoint Medical Corporation's pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
